
FBIO
Fortress Biotech Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.990
Open
1.940
VWAP
1.95
Vol
143.56K
Mkt Cap
58.25M
Low
1.900
Amount
280.35K
EV/EBITDA(TTM)
--
Total Shares
20.41M
EV
35.41M
EV/OCF(TTM)
--
P/S(TTM)
0.77
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
14.53M
-2.43%
--
--
19.29M
+31.83%
--
--
38.75M
+156.31%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Fortress Biotech, Inc. (FBIO) for FY2025, with the revenue forecasts being adjusted by 17.38% over the past three months. During the same period, the stock price has changed by 17.26%.
Revenue Estimates for FY2025
Revise Upward

+17.38%
In Past 3 Month
Stock Price
Go Up

+17.26%
In Past 3 Month
2 Analyst Rating

407.61% Upside
Wall Street analysts forecast FBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBIO is 10.00 USD with a low forecast of 4.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy

407.61% Upside
Current: 1.970

Low
4.00
Averages
10.00
High
16.00

407.61% Upside
Current: 1.970

Low
4.00
Averages
10.00
High
16.00
Roth MKM
Jason Wittes
Strong Buy
Reiterates
$15 → $16
2025-03-11
Reason
Roth MKM
Jason Wittes
Price Target
$15 → $16
2025-03-11
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$24 → $26
2024-11-18
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$24 → $26
2024-11-18
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Fortress Biotech Inc (FBIO.O) is -1.57, compared to its 5-year average forward P/E of -3.95. For a more detailed relative valuation and DCF analysis to assess Fortress Biotech Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.95
Current PE
-1.57
Overvalued PE
1.68
Undervalued PE
-9.57
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.89
Current EV/EBITDA
-1.26
Overvalued EV/EBITDA
0.21
Undervalued EV/EBITDA
-1.99
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
1.78
Current PS
0.60
Overvalued PS
3.50
Undervalued PS
0.06
Financials
Annual
Quarterly
FY2025Q1
YoY :
+0.84%
13.14M
Total Revenue
FY2025Q1
YoY :
-38.97%
-22.32M
Operating Profit
FY2025Q1
YoY :
-36.73%
-24.69M
Net Income after Tax
FY2025Q1
YoY :
-53.40%
-0.48
EPS - Diluted
FY2025Q1
YoY :
-22.94%
-19.56M
Free Cash Flow
FY2025Q1
YoY :
+16.25%
55.44
Gross Profit Margin - %
FY2025Q1
YoY :
+14.01%
-154.66
FCF Margin - %
FY2025Q1
YoY :
-37.25%
-187.92
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
129.0K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
1.4M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
129.0K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
1.4M
USD
Months
FBIO News & Events
Events Timeline
2025-03-17 (ET)
2025-03-17
09:00:31
Fortress Biotech, Partex enter collaboration for asset identification

2025-03-17
08:57:36
Fortress Biotech, Partex enter collaboration for asset identification, evaluatio

2025-03-10 (ET)
2025-03-10
11:13:29
Checkpoint Therapeutics jumps after deal to be acquired by Sun Pharma

Sign Up For More Events
Sign Up For More Events
News
9.0
07-14NewsfilterJourney Medical Corporation Announces Expanded Payer Coverage for Emrosi™
9.0
07-07NewsfilterMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
1.0
06-24NewsfilterJourney Medical to Join Russell 2000® and Russell 3000® Indexes
Sign Up For More News
People Also Watch

BEST
BEST Inc
0
USD
-0.72%

SSBI
Summit State Bank
11.676
USD
+0.66%

ARKR
Ark Restaurants Corp
8.550
USD
-0.81%

BEDU
Bright Scholar Education Holdings Ltd
1.845
USD
0.00%

OMIC
Singular Genomics Systems Inc
0
USD
+0.25%

OPI
Office Properties Income Trust
0.277
USD
-13.95%

NVNI
Nvni Group Ltd
0.420
USD
+1.20%

KSCP
Knightscope Inc
7.010
USD
-6.53%

MDIA
Mediaco Holding Inc
1.330
USD
+0.83%

CLST
Catalyst Bancorp Inc
12.380
USD
+0.24%
FAQ

What is Fortress Biotech Inc (FBIO) stock price today?
The current price of FBIO is 1.97 USD — it has increased 1.55 % in the last trading day.

What is Fortress Biotech Inc (FBIO)'s business?

What is the price predicton of FBIO Stock?

What is Fortress Biotech Inc (FBIO)'s revenue for the last quarter?

What is Fortress Biotech Inc (FBIO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Fortress Biotech Inc (FBIO)'s fundamentals?

How many employees does Fortress Biotech Inc (FBIO). have?
